MARKET

AVTX

AVTX

Avalo Therapeutics Inc
NASDAQ
10.00
+0.04
+0.40%
Closed 16:00 12/04 EST
OPEN
9.95
PREV CLOSE
9.96
HIGH
10.26
LOW
9.81
VOLUME
77.95K
TURNOVER
--
52 WEEK HIGH
34.46
52 WEEK LOW
3.950
MARKET CAP
103.94M
P/E (TTM)
-0.2741
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at AVTX last week (1125-1129)?
Weekly Report · 3d ago
Weekly Report: what happened at AVTX last week (1118-1122)?
Weekly Report · 11/25 09:30
Weekly Report: what happened at AVTX last week (1111-1115)?
Weekly Report · 11/18 09:29
Avalo Therapeutics receives $69.4M in proceeds from full exercise of private placement warrants
Seeking Alpha · 11/12 14:09
Avalo Therapeutics receives $69.4M in proceeds from exercise of warrants
TipRanks · 11/12 13:01
Avalo Therapeutics Has Received $69.4M In Gross Proceeds From The Full Exercise Of The Warrants Issued In March 2024 Private Placement
Benzinga · 11/12 12:49
Press Release: Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants
Dow Jones · 11/12 12:00
Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants
Barchart · 11/12 06:00
More
About AVTX
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL- 1β is a central driver in the inflammatory process. Quisovalimab is a fully human monoclonal antibody (mAb), directed against human LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes). AVTX-008 is a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. AVTX-008 is differentiated by having specific binding to BTLA, with no binding to LIGHT or CD160.

Webull offers Avalo Therapeutics Inc stock information, including NASDAQ: AVTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AVTX stock methods without spending real money on the virtual paper trading platform.